Passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic metabolic disorders


Agios (NASDAQ: AGIO) is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging the company’s knowledge of metabolism, biology and genomics.


Year Invested: 2008
Location: Cambridge, Mass.
Visit: www.agios.com

Recent News

February 16, 2017
Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones

February 9, 2017
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2016 Financial Results on February 16, 2017

January 9, 2017
Agios Announces Key Upcoming Milestones to Support Evolution to a Commercial Stage Biopharmaceutical Company in 2017

Read More News

Associated Team Members

Kevin Starr
Partner

Craig Muir
Partner/Chief Technology Officer

Cary Pfeffer, M.D.
Partner